GlassScriptPhysician profile
Michael J Billock
NPI 1962164046
$4,742.64
in general payments reported to CMS, 2019-2025
17 companies · $1,069 in 2025
The $1,069 reported for 2025 was more than what 82% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $300 · 2022: $1,386 · 2023: $860 · 2024: $1,127 · 2025: $1,069.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,029 · Education: $27.34.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,029.34 |
| Education | $27.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $722.38 | 2021-2024 | Ingrezza |
| Janssen Pharmaceuticals, INC | $611.44 | 2022-2025 | Invega Sustenna |
| Lundbeck LLC | $605.10 | 2022-2025 | Rexulti, Abilify Maintena |
| Otsuka America Pharmaceutical, INC. | $559.87 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Teva Pharmaceuticals USA, INC. | $538.50 | 2021-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $425.40 | 2022-2025 | Caplyta |
| Abbvie INC. | $366.80 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $296.79 | 2025 | Cobenfy |
| Acadia Pharmaceuticals INC | $143.68 | 2024 | Nuplazid |
| Alkermes, INC. | $119.30 | 2022 | |
| Almatica Pharma LLC | $76.15 | 2021-2022 | |
| Vanda Pharmaceuticals INC. | $75.06 | 2021-2022 | |
| Noven Therapeutics, LLC | $55.48 | 2021-2022 | |
| Corium, LLC | $54.56 | 2022-2023 | Azstarys |
| Indivior INC. | $40.72 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $34.28 | 2022 | |
| Ironshore Pharmaceuticals INC. | $17.13 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Billock listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.